Distribution Agreement Widens Access to High Throughput Antibody Screening and Characterisation Solutions 

Carterra, Inc, a world leader in label-free high throughput antibody screening and characterisation, has announced that it has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer, Inc, a global leader committed to innovating for a healthier world. With the agreement, PerkinElmer will market, sell, and service Carterra’s flagship LSA high-throughput surface plasmon resonance (SPR) platform and software used for accelerating the discovery of therapeutic antibodies.

This move will assist Carterra in meeting growing customer demand by leveraging PerkinElmer’s long-standing channel infrastructure in the region. It will also add additional tools to PerkinElmer’s growing portfolio of science and biologics discovery offerings, which includes its world leading BioLegend antibody and reagent technologies. 

This new agreement builds on the equity investment PerkinElmer made in Carterra last December, which has resulted in several collaborations between the companies involving assay development and software integration projects over the past year.

Commenting on this latest distribution arrangement, Alan Fletcher, Senior Vice President, Life Science, PerkinElmer, said: “We are delighted to add the distribution of Carterra’s highly innovative LSA technology to help our Asia-Pacific and Oceania customers further streamline and advance their biologic and biotherapeutic discovery and development work.” 

“Carterra recognised early on that Asia-Pacific and Oceania would be important markets for our game changing biologics discovery products and we are at the point where we need additional reach and channel power to help us take our customer delivery there to the next level,” stated Tim Germann, Chief Commercial Officer at Carterra. “We are excited to collaborate with PerkinElmer to add that extra horsepower in sales, marketing and service as well as benefit from their deep life science expertise across drug development workflows.” 

More information online